Microbot Medical Stock Rises After Completing ACCESS-PVI Trial

Zacks10-17

Microbot Medical, Inc. MBOT has successfully completed patient enrollment and follow-up in its ACCESS-PVI human clinical trial, which evaluates the performance and safety of the LIBERTY Endovascular ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2476972923?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/U4GUduRjeOg4nMm.oXfQdA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1a9a38eb6d9cb218a416cc7ef77b5823","is_english":true,"pubTime":"2024-10-17 00:22","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2476972923","market":"us","top_or_hot":-1,"title":"Microbot Medical Stock Rises After Completing ACCESS-PVI Trial","media":"Zacks","content":"<div>\n<p>Microbot Medical, Inc. MBOT has successfully completed patient enrollment and follow-up in its ACCESS-PVI human clinical trial, which evaluates the performance and safety of the LIBERTY Endovascular ...</p>\n\n<a href=\"https://finance.yahoo.com/news/microbot-medical-stock-rises-completing-162200257.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microbot Medical Stock Rises After Completing ACCESS-PVI Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrobot Medical Stock Rises After Completing ACCESS-PVI Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-17 00:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/microbot-medical-stock-rises-completing-162200257.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Microbot Medical, Inc. MBOT has successfully completed patient enrollment and follow-up in its ACCESS-PVI human clinical trial, which evaluates the performance and safety of the LIBERTY Endovascular ...</p>\n\n<a href=\"https://finance.yahoo.com/news/microbot-medical-stock-rises-completing-162200257.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BN0W2W23.USD","symbol_name":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/microbot-medical-stock-rises-completing-162200257.html","article_id":"2476972923","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/U4GUduRjeOg4nMm.oXfQdA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1a9a38eb6d9cb218a416cc7ef77b5823"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476972923","pubTimestamp":1729095720,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Microbot Medical, Inc. MBOT has successfully completed patient enrollment and follow-up in its ACCESS-PVI human clinical trial, which evaluates the performance and safety of the LIBERTY Endovascular Robotic Surgical System in Peripheral Vascular Interventions.The company is now set to file its 510 submission with the FDA by the end of 2024 and plans to accelerate its go-to-market strategy upon clearance.Shares of MBOT have plunged 41.2% year to date against the industry’s 7.8% growth. The S&P 500 has risen 22.9% in the same time frame.Microbot Medical’s successful completion of the ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System signals positive investor sentiment. The LIBERTY system's potential to revolutionize endovascular procedures by reducing costs, improving physician experience and enabling remote operations positions it as a groundbreaking advancement, driving positive price performance.Significance of MBOT's ACCESS-PVI Trial for LIBERTY System. L","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","ADUS":"爱德斯","BK4082":"医疗保健设备","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","DGX":"奎斯特诊疗","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","BK4583":"猴痘概念","MBOT":"Microbot Medical Inc","BK4588":"碎股","BK4196":"保健护理服务","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","PVI":"Invesco VRDO Tax-Free ETF","RDNT":"RadNet","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC"},"translate_title":"完成ACCESS-PVI试验后Microbot Medical股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RDNT":1,"PVI":1,"MBOT":1,"DGX":1,"ADUS":0.9},"content_text":"Microbot Medical, Inc. MBOT has successfully completed patient enrollment and follow-up in its ACCESS-PVI human clinical trial, which evaluates the performance and safety of the LIBERTY Endovascular Robotic Surgical System in Peripheral Vascular Interventions.\nThe company is now set to file its 510(k) submission with the FDA by the end of 2024 and plans to accelerate its go-to-market strategy upon clearance.\nLikely Trend of MBOT Stock Following the News\nFollowing the news, shares of MBOT rose 0.3% to $0.96 at yesterday’s closing.\nShares of MBOT have plunged 41.2% year to date against the industry’s 7.8% growth. The S&P 500 has risen 22.9% in the same time frame.\nMicrobot Medical’s successful completion of the ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System signals positive investor sentiment. The LIBERTY system's potential to revolutionize endovascular procedures by reducing costs, improving physician experience and enabling remote operations positions it as a groundbreaking advancement, driving positive price performance.\nImage Source: Zacks Investment Research\nSignificance of MBOT's ACCESS-PVI Trial for LIBERTY System\nThe successful completion of the ACCESS-PVI trial marks a significant milestone for Microbot Medical, demonstrating the effectiveness of the LIBERTY system in clinical settings. This accomplishment not only strengthens the company’s position in the healthcare market but also supports the 510(k) submission to the FDA and sets the stage for future commercialization efforts. The encouraging results from the trial, along with positive feedback from physicians, signify strong prospects for Microbot Medical and its innovative robotic surgical technologies.\nManagement expressed satisfaction with the LIBERTY system’s performance in its clinical trial.  It plans to present results in early 2025. The company sees the trial's conclusion as a major achievement and is focused on finalizing the FDA submission and preparing for commercialization.\nWith plans to build a commercial infrastructure and hire experienced healthcare executives for sales, Microbot is preparing for a potential launch in the second quarter of 2025, following the anticipated FDA approval.\nMarket Prospects Favoring MBOT\nPer a report in Grand View Research, the global peripheral vascular devices market size is estimated to be worth $10.4 billion in 2024. It is anticipated to reach $14.8 billion by 2030 at a CAGR of 5.9%. \nThe robust growth is likely to be driven by the increasing incidence of cardiac diseases, the rising global geriatric population base triggering incidence rates of target diseases, novel product launches and an increase in collaboration and mergers by key players.\nRecent Developments at Microbot Medical\nLast month, Microbot Medical reached the midpoint of its ACCESS-PVI pivotal human clinical trial, successfully enrolling and completing follow-ups for 50% of the participants. This trial evaluates the LIBERTY Endovascular Robotic Surgical System in patients undergoing Peripheral Vascular Interventions.\nIn August, Microbot Medical entered a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using its LIBERTY Endovascular Robotic System. Following positive results from Phase 1, which demonstrated LIBERTY's technical capabilities and potential applications, the new phase will focus on developing the system's ability to perform simulated cardiovascular interventional procedures across two Corewell Health sites located five miles apart.\nThe same month, Microbot Medical agreed with Emory University to explore the potential for collaboration on autonomous robotics in endovascular procedures. Under this agreement, Emory University will investigate the feasibility of integrating the LIBERTY Endovascular Robotic Surgical System with an imaging system to create an autonomous robotic system for these procedures.\nZacks Rank & Key Picks\nCurrently, Microbot Medical carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Addus HomeCare ADUS, Quest Diagnostics (DGX) and RadNet (RDNT). While Addus HomeCare carries a Zacks Rank #1 (Strong Buy), Quest Diagnostics and RadNet carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nAddus HomeCare has an estimated long-term growth rate of 12.1%. ADUS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 11.5%.\nAddus HomeCare shares have gained 85.5% compared with the industry's 16.9% growth year to date.\nQuest Diagnostics has an estimated long-term growth rate of 6.8%. DGX's earnings surpassed estimates in each of the trailing four quarters, with the average being 3.3%.\nQuest Diagnostics has gained 42% compared with the industry's 14.9% growth year to date.\nRadNet’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 98.2%.\nRDNT's shares have surged 93.7% year to date compared with the industry’s 14.8% growth.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nQuest Diagnostics Incorporated (DGX) : Free Stock Analysis Report\nAddus HomeCare Corporation (ADUS) : Free Stock Analysis Report\nRadNet, Inc. (RDNT) : Free Stock Analysis Report\nMicrobot Medical Inc. (MBOT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476972923"}